The Conversation (0)
InVivo Therapeutics Enrolls Sixth Patient into The INSPIRE Study
Feb. 23, 2016 08:57AM PST
Biotech InvestingInVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that a sixth patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Missouri.
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that a sixth patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Missouri.
According to the news:
Wilson (Zack) Ray, M.D., Associate Professor of Neurosurgery and a member of The INSPIRE Study Steering Committee, performed the implantation approximately 10 hours after the injury occurred. Paul Santiago, M.D., is the Principal Investigator at this site.
Dr. Ray commented:
We were able to get the patient into the operating room in such an expeditious manner thanks to the experienced trauma and neurosurgical teams at the Barnes-Jewish Hospital. The implantation procedure was straightforward and the patient is recovering well. I look forward to following the patient’s progress.